Glossary

A B C D E F G H I J K L M Current PageN O P Q R S T U V W X Y Z

NCAB

National Cancer Advisory Board

NCI

National Cancer Institute, NIH, DHHS

NCI-DESIGNATED COMPREHENSIVE CANCER CENTER

An institution which is designated by NCI as a comprehensive or clinical cancer center and is eligible to conduct IND drug studies

NCIC

National Cancer Institute of Canada (now known as the Canadian Cancer Trials Group)

NCORP

NCI Community Oncology Research Program. NCORP is a community-based program that builds upon the scope and activities of NCI’s previously supported community networks.

NCTN

National Clinical Trials Network. Founded in 2014 by NCI after a report by the Institute of Medicine on the cooperative group system called for a more effective and efficient way to run trials

NDA

New Drug Application. The formal process by which the FDA makes a previously investigational drug generally available to patients and physicians for specific indications.

NDI

National Death Index

NEW DRUG STUDY GROUP

A group of highly-qualified clinical researchers at an institution approved by IDB to participate in NCI’s drug development program.

NIA

Noninstitutional Investigator Agreement. An OHRP-authorized document entered into between a signatory institution and a non-institutional affiliate investigator (e.g., private practitioner), which assures compliance with 45 CFR 46 for a specified activity (e.g., cooperative oncology group trials).

NIH

National Institutes of Health, DHHS

NRG ONCOLOGY

An adult clinical trial group sponsored by the NCI, supporting research as one of the five members of the NCTN.

NSC NUMBER

A universally recognized unique identification number that identifies a specific compound throughout the entire lifespan of that specific agent (not just while it is investigational). The "NSC" refers to the former Cancer Chemotherapy National Service Center.